2019 SITC: T-cell receptor alpha and beta repertoire profiling using an augmented transcriptome
The promise of immunotherapy has revealed the need for comprehensive profiling of the tumor and its immune microenvironment. This includes analysis of the T-cell receptor (TCR) repertoire, which has traditionally not been feasible with an exome/transcriptome platform. To address this challenge, we developed ImmunoID NeXT, an augmented, immuno-oncology optimized exome/transcriptome platform designed to provide a more comprehensive view of the tumor and tumor microenvironment (TME) from limited FFPE tumor biopsies. This includes profiling both the TCR a and b chains. We show that ImmunoID NeXT accurately and reproducibly profiles abundant clones, and provides information on the diversity of T-cells in tumor samples.